Breast Cancer

  • E. E. Kim


Breast cancer is the most common malignancy of women in North America and is the leading cause of death in women between the ages of 40 and 55. In 1995 approximately 182 000 women in the United States will have been diagnosed with breast cancer, and 46 000 women will die of this disease [20].


Breast Cancer Positron Emission Tomography Sentinel Node Axillary Lymph Node Primary Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL (1993) Evaluation of breast masses and axillary lymph nodes with F-18 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743–750PubMedGoogle Scholar
  2. 2.
    Balon HR, Fink-Bennett D, Stoffer SS (1992) Tc-99m sestamibi uptake by recurrent Hunthle cell carcinoma of the thyroid. J Nucl Med 33:1393–1395PubMedGoogle Scholar
  3. 3.
    Bassa P, Kim EE, Inoue T, Wiong FCL, Korkmaz M, Yang DJ, Wong W-H, Hicks KW, Buzdar AU, Podoloff DA (1996) Evaluation of preoperative chemotherapy using PET with F-18 fluorodeoxyglucose in breast cancer. J Nucl Med 37:931–938PubMedGoogle Scholar
  4. 4.
    Bird R, Wallace T, Yankaskas B (1992) Analysis of cancers missed at screening mammography. Radiology 184:613–617PubMedGoogle Scholar
  5. 5.
    Boetes C, Mus RDM, Holland R, Barentsz JO, Strijk SP, Wobbes T, Hendriks JHCL, Ruys SHJ (1995) Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 197:743–747PubMedGoogle Scholar
  6. 6.
    Dehdashti F, Mortimer JE, Siegel BA, Griffieth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler D, Katzenellenbogan JA, Welch MJ (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766–1774PubMedGoogle Scholar
  7. 7.
    Harms SE, Flaming DP, Hesley KL (1993) MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 187:493–501PubMedGoogle Scholar
  8. 8.
    Hawkins RA, Hoh C, Dahlbom M (1991) PET cancer evaluation with FDG. J Nucl Med 32:1555–1558PubMedGoogle Scholar
  9. 9.
    Inoue T, Kim EE, Wallace S, Yang DJ, Wong FCL, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff DA (1996) PET using F-18 fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer. Cancer Biotherapy Radiopharm 11:235–245CrossRefGoogle Scholar
  10. 10.
    Jackson V (1990) The role of US in breast imaging. Radiology 177:305–311PubMedGoogle Scholar
  11. 11.
    Khalkhali I, Cutrone JA, Mena IG, Diggles IE, Venegas RJ, Vargas HI, Jackson BL, Khalkhali S, Moss JF, Klein SR (1995) Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 196:421–426PubMedGoogle Scholar
  12. 12.
    Kopans DB (1992) The positive predictive value of mammography. AJR 158:521–526PubMedGoogle Scholar
  13. 13.
    Maublant J, de Latour M, Mestas D, Clemenson A, Charrier S, Feillel V (1996) Tc-99m sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 37:922–925PubMedGoogle Scholar
  14. 14.
    McLean RG, Ege GN (1986) Prognostic value of axillary lymphoscintigraphy in breast cancer patients. J Nucl Med 27:1116–1124PubMedGoogle Scholar
  15. 15.
    Piccolo S, Lastoria S, Mainolfi C, Muto P, Bazzicalupo L, Salvatore M (1995) Tc-99m methylene diphosphonate scintimammography to image primary breast cancer. J Nucl Med 36:718–724PubMedGoogle Scholar
  16. 16.
    Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J (1995) Tc-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 36:1758–1765PubMedGoogle Scholar
  17. 17.
    Uren RF Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, Renwick SB (1995) Mammary lymphoscintigraphy in breast cancer. J Nucl Med 36:1775–1780PubMedGoogle Scholar
  18. 18.
    Wahl RL, Cody R, Fisher S (1991) FDG uptake before and after estrogen receptor stimulation: feasibility studies for functional receptor imaging. J Nucl Med 32:1011–1015Google Scholar
  19. 19.
    Waxman AD, Ramanna L, Memsic LD (1993) Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 34:18–23PubMedGoogle Scholar
  20. 20.
    Wingo PA, Tong T, Bolden S (1995) Cancer statistics. Cancer 5:8–30Google Scholar
  21. 21.
    Worsley DF, Lentle BC (1993) Uptake ofi Tc-99m MDP in primary amyloidosis with a review of the mechanisms of soft-tissue localization of bone-seeking radiopharmaceuticals. J Nucl Med 34:1612–1615PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • E. E. Kim

There are no affiliations available

Personalised recommendations